. 2022 Sep 27;10:1010824. doi: 10.3389/fbioe.2022.1010824

TABLE 3.

Subgroup analysis of outcomes.

Outcome/subgroup			OS	PFS	Treatment response			Mortality	Resection
Outcome/subgroup			OS	PFS	PR	PD	SD	Mortality	Resection
BCLC Stage subgroup analysis	BCLC A-B ^a	HR/RR	0.58	0.56	3.23	0.38	0.82	0.63	2.10
		95%CI	[0.43, 0.78]	[0.45, 0.70]	[1.63, 6.38]	[0.26, 0.58]	[0.64, 1.06]	[0.12, 3.21]	[1.33, 3.32]
		p value	*0.0004*	*<0.00001*	*0.0008*	*<0.00001*	0.13	0.57	*0.002*
		I²	n/a	0%	49%	0%	0%	0%	0%
	BCLC C ^b	HR/RR	0.42	0.42	2.51	0.6	0.81	0.36	6.66
		95%CI	[0.22, 0.81]	[0.21, 0.86]	[1.65, 3.81]	[0.36, 0.98]	[0.62, 1.07]	[0.02, 8.46]	[1.75, 25.30]
		p value	*0.01*	*0.02*	*<0.0001*	*0.04*	0.14	0.53	*0.005*
		I²	83%	86%	23%	66%	0%	n/a	0%
HAIC methods subgroup analysis	With port system ^c	HR/RR	0.36	0.09	2.64	0.41	1.18	0.36	3.26
		95%CI	[0.17, 0.79]	[0.03, 0.27]	[1.44, 4.85]	[0.16, 1.07]	[0.72, 1.94]	[0.02, 8.46]	[0.14, 76.10]
		p value	*0.01*	*<0.0001*	*0.002*	0.07	0.52	0.53	0.46
		I²	67%	n/a	0%	59%	0%	n/a	n/a
	Without port system ^d	HR/RR	0.60	0.61	3.03	0.55	0.71	0.63	2.68
		95%CI	[0.50, 0.72]	[0.52, 0.72]	[2.11, 4.35]	[0.40, 0.76]	[0.56, 0.90]	[0.12, 3.21]	[1.41, 5.08]
		p value	*<0.00001*	*<0.00001*	*<0.00001*	*0.0003*	*0.006*	0.57	*0.003*
		I²	0%	5%	47%	53%	43%	0%	24%
HAIC regimen subgroup analysis	Using FOLFOX-HAIC ^e	HR/RR	0.48	0.51	2.67	0.50	0.82	0.56	2.37
		95%CI	[0.32, 0.72]	[0.36, 0.73]	[2.00, 3.57]	[0.34, 0.74]	[0.68, 0.98]	[0.13, 2.38]	[1.54, 3.66]
		p value	0.0004	0.0002	*<0.00001*	0.0005	0.03	0.43	<0.0001
		I²	75%	72%	0%	0%	0%	0%	17%
	Using cisplatin + fluorouracil combined HAIC ^f	HR/RR	0.53	n/a	3.09	0.57	1.14	n/a	n/a
		95%CI	[0.30, 0.92]	n/a	[0.66, 14.35]	[0.25, 1.31]	[0.63, 2.06]	n/a	n/a
		p value	0.03	n/a	0.15	0.19	0.66	n/a	n/a
		I²	0%	n/a	34%	40%	0%	n/a	n/a

, Reference (Li et al., 2022; He et al., 2017)

Reference (An et al., 2021; Hu et al., 2020; Li et al., 2021)

References (Sumie et al., 2003; Kim et al., 2010; Hu et al., 2020)

References (He et al., 2017; An et al., 2021; Li et al., 2021; Chen et al., 2022; Li et al., 2022)

References (He et al., 2017; Hu et al., 2020; An et al., 2021; Li et al., 2021; Li et al., 2022)

References (Sumie et al., 2003; Kim et al., 2010).

BCLC, barcelona clinic liver cancer; HR, hazard ratio; RR, risk ratio; OS, overall survival; PFS, progression-free survival; PR, partial response; PD, progressive disease; SD, stable disease.

To highlight the results with statistical significance.